Navigation Links
Opto Circuits Successfully Completes Acquisition of Cardiac Science
Date:12/3/2010

MILWAUKEE, Wis. and BANGALORE, India, Dec. 3, 2010 /PRNewswire/ -- Opto Circuits (India) Ltd. [BSE Code: 532391; NSE: OPTOCIRCUI] today announced that it has completed the merger of its wholly-owned subsidiary, Jolt Acquisition Company, into Cardiac Science Corporation (Nasdaq: CSCX).  As a result of the transaction, Cardiac Science has become a wholly-owned subsidiary of Opto Circuits.

The merger follows (i) Opto Circuits' acquisition, through a tender offer by Jolt Acquisition, of approximately 77% of Cardiac Science's outstanding common stock at a price of $2.30 per share, net to the seller in cash, without interest and less any required withholding taxes and (ii) Jolt Acquisition's subsequent exercise of its top-up option, pursuant to which it acquired directly from Cardiac Science a sufficient amount of shares to effect a short-form merger under Delaware law, that is, without a vote or meeting of the remaining Cardiac Science stockholders.  In the merger, each remaining outstanding share of Cardiac Science stock was cancelled and (other than shares held in the treasury of Cardiac Science, shares owned by Opto Circuits, Jolt Acquisition or any other direct or indirect wholly-owned subsidiary of Opto Circuits, or shares held by stockholders who properly demand and perfect appraisal rights under Delaware law) converted into the right to receive $2.30 per share, net to the holder in cash, without interest, and less any required withholding taxes.

Opto Circuits intends to delist and de-register Cardiac Science's common stock as promptly as practicable following the effective time of the merger, and Cardiac Science's common stock will cease to be traded on NASDAQ. Detailed instructions will be mailed to former Cardiac Science stockholders who did not tender their shares into the tender offer outlining the steps to be taken to obtain the merger consideration or exercise appraisal rights under Delaware law.

About Opto CircuitsOpto Circuits (India) Ltd. (OCI) (BSE Code: 532391; NSE Symbol: OPTOCIRCUI) is an Indian MNC in the business of design, development, manufacture and marketing of healthcare equipment and interventional products. The product profile includes pulse oximeters, patient monitoring systems, sensors, digital thermometers anesthesia and respiratory care equipment, stents, catheters and other innovative products. Some of the well-known brands marketed by Opto Circuits are Criticare, Mediaid, Unetixs and Eurocor. It is presently a Group of 14 companies with a consolidated total sales of USD $243 million/Rs.1077 crores (FY10) and it is headquartered in Bengaluru, Karnataka, India. Its key markets are the US, Europe and South East Asia. It was ranked as one amongst 200 Best Under a Billion companies in AsiaPac by Forbes Asia in 2009, 2008. Visit us at www.optoindia.com.

About Cardiac ScienceCardiac Science develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AED), electrocardiograph devices (ECG/EKG), cardiac stress treadmills and systems, diagnostic workstations, Holter monitoring systems, hospital defibrillators, vital signs monitors, cardiac rehabilitation telemetry systems, and cardiology data management systems (informatics) that connect with hospital information (HIS), electronic medical record (EMR), and other information systems. The company sells a variety of related products and consumables and provides a portfolio of training, maintenance, and support services. Cardiac Science, the successor to the cardiac businesses that established the trusted Burdick®, HeartCentrix®, Powerheart®, and Quinton® brands, is headquartered in Bothell, Washington. With customers in more than 100 countries worldwide, the company has operations in North America, Europe, and Asia. For information, call 425.402.2000 or visit http://www.cardiacscience.com.

Forward-Looking StatementsThis release contains forward-looking statements. Such statements are based on the current assumptions and expectations of Opto Circuits' management and are neither promises nor guarantees. The words "believe," "expect," "intend," "anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. There can be no assurance that management's estimates of future results will be achieved. Actual results and performance may vary significantly from those expressed or implied in such statements. The actual results of the acquisition could vary materially as a result of a number of factors, including the possibility that various closing conditions for the transaction may not be satisfied or waived. Other factors that may cause actual results to differ materially include those set forth in the reports that Cardiac Science files from time to time with the Securities and Exchange Commission, including Cardiac Science's annual report on Form 10-K for the year ended December 31, 2009 and quarterly and current reports on Form 10-Q and 8-K. Contact Information:Opto Circuits Contact:Thomas Dietiker, (310) 561-8468IR: ir@optoindia.comMedia: media@optoindia.comT: +91 80 2852 1040/41/42
'/>"/>

SOURCE Opto Circuits (India) Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Opto Circuits Acquisition of Unetixs Vascular Creates Strong Synergies for Criticare Systems
2. Opto Circuits to Acquire Cardiac Science
3. Teriflunomide Successfully Reduces Relapses and is Well Tolerated in Multiple Sclerosis Patients
4. Medisafe 1 Technologies Successfully Tests Prototype of Patented Syringe Locking Device
5. Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Penwest Pharmaceuticals
6. Transcatheter Technologies Successfully Performs in Vivo Implantation of the Trinity Transapical Aortic Valve System
7. Omeros Successfully Unlocks Orphan GPCRs
8. NeuroDerm Successfully Completes Enrollment and Dosing in a Phase 1 Clinical Study of ND0611 Dermal Patch for Parkinsons Disease
9. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
10. MedAvante Opens Moscow Office and Successfully Completes First Centralized Ratings Assessment
11. Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2017)... , May 30, 2017 Hill-Rom Holdings, Inc. (NYSE: ... Annual Global Healthcare Conference on Tuesday, June 13, 2017, in ... Greisch , Hill-Rom,s president and chief executive officer, is scheduled ... live audio webcast can be accessed at http://ir.hill-rom.com/events.cfm . ... of the live event through September 13, 2017. ...
(Date:5/26/2017)...  In response to the opioid epidemic in ... working with Pfizer to make up to 1 million ... community health centers, free and charitable clinics, public health ... "Pfizer has a long-standing commitment to improving health outcomes ... through educational activities," said Caroline Roan , vice ...
(Date:5/22/2017)... , May 22, 2017  As the specialty ... whole continue to make the revolutionary shift from ... important for ensuring positive patient outcomes and shaping ... are shifting focus away from clinical trials and ... of long-term specialty drug therapy utilization in precise ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... June 23, 2017 , ... ... Flood Insurance offerings. With the Federal Emergency Management Agency’s (FEMA) recent update of ... United States. In 2012, the Biggert-Waters Act was enacted to reflect the actual ...
(Date:6/23/2017)... ... June 23, 2017 , ... Jusino ... services to communities in the greater Chicago metropolitan area, is embarking on a ... underprivileged youth in Chicago. , Founded in 1897, Hephzibah Children’s Association is one ...
(Date:6/22/2017)... ... June 22, 2017 , ... Branches, Inc. has been ... $245,000 in grant funding to support its programs focused on providing opportunity to low-income ... awarded a grant by the Foundation of $15,000 to support its , Climb to ...
(Date:6/22/2017)... ... June 22, 2017 , ... Children’s National Health ... Association (AHA) to launch a Rheumatic Heart Disease Center, with the goal of ... rheumatic heart disease (RHD) in high-risk, financially disadvantaged countries and low-income communities across ...
(Date:6/22/2017)... , ... June 22, 2017 , ... A June 12 ... to a correspondent concerned about an apparent lack of oral hygiene by an aged ... in geriatrics and dementia-related matters, suggests a number of steps, including scheduling a dentist ...
Breaking Medicine News(10 mins):